GLP-1 Agonist Development: Endpoint Strategies to Help Differentiate Your Drug
The development of GLP-1 agonists for diabetes and obesity management continues to transform patient care, but in today’s competitive landscape, standing out is more critical than ever. In this webinar, the expert speakers will share strategies for leveraging innovative endpoint solutions to enhance the safety, efficacy and patient-focused value of GLP-1 clinical trials.
Attendees will gain valuable insights into:
- How digital endpoints can provide high-quality data to detect safety concerns
- Evaluating therapeutic benefits
- Generating compelling trial outcomes
Unlock the potential of your GLP-1 clinical trials with expert insights—reserve your spot in our exclusive webinar today!
Session information:
Time:
- 11:00 a.m. – 12:00 p.m. ET (NA-East)
- 16:00 – 17:00 GMT (UK)
- 17:00 – 18:00 CET (EU-Central)
Speakers
Jessica Emerson, Ph.D., M.S.
Senior Scientific Advisor, eCOA Science and Consulting at Clario
Dr. Jessica Emerson is a behavioral scientist with over 15 years of experience in behavioral and social science research focusing on the role of technology in measuring and intervening on health behaviors to improve health among patients with obesity and diabetes. She also has extensive experience in eCOA database design and management. Jessica has been with Clario since 2021. As a Senior Scientific Advisor, she supports sponsors and CROs in eCOA design best practices and preliminary study set-up to optimize the reliability of eCOA data. Jessica received her undergraduate degree in psychology from Tufts University, and she completed her MS in Cognitive Science and her PhD in Behavioral and Social Health Sciences at Brown University. She completed a post-doctoral research fellowship at the Miriam Hospital at the Diabetes and Weight Loss Research Center.
Mark W. Tengowski, DVM, M.S., Ph.D.
Director Medical & Scientific Affairs, Medical Imaging at Clario
Dr. Mark W. Tengowski’s current responsibilities include clinical development and trial experiences in SLD/MASH (formerly NAFLD/NASH) and biliary cholangitis; Crohn’s disease, perianal fistula and ulcerative colitis; osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, spondyloarthritis, psoriatic arthritis and bone age; and women’s health, including endometriosis, uterine fibroids, endometrial thickness and breast volume and density using various MRI, XR and CT imaging and clinical response assessments. Dr. Tengowski began his industry career with Pfizer (1999-2007) working in Drug Safety Evaluation (Groton) and Global Clinical Technologies (Ann Arbor). In 2007, he began his imaging core lab service starting at VirtualScopics (2007-2013) and Clario (formerly Bioclinica/ERT, 2016 to present). Dr. Tengowski is a 1992 graduate of the University of Wisconsin School of Veterinary Medicine with graduate training in both pharmacology (MS, 1994) and endocrinology and reproductive physiology (PhD, 1997) from the UW-Madison Graduate School. Dr. Tengowski holds veterinary medical licenses in WI and NY and is accredited by the USDA (Category II). He is a member of the AASLD.
Judith Narisi, BSN, RN
Senior Medical Scientific Affairs Associate at Clario
Judy Narisi is a seasoned healthcare professional with over two decades of experience in clinical research. Trained as a critical care RN, Judy’s research journey began in 2004 as a Study Coordinator, progressing to safety event case management and ultimately event adjudication in 2006. She has held key roles at PharmaNet, Johnson & Johnson and ICON, where her team reviewed 9,000+ cases for a large CV outcomes trial in patients with type II diabetes at high CV risk that compared liraglutide with placebo using a primary composite endpoint of three-point major adverse CV events. Judy began her tenure at Clario as a Senior Director of adjudication services and currently serves as a Senior Medical Affairs Associate for Adjudication. She has successfully managed a team that has been effective in rescuing several large programs and contributed to the approval of several pharmaceutical drugs supported by the adjudication of thousands of events. Judy received her nursing degree from Gwynedd Mercy University in Pennsylvania.